Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ironstomach
2024-519738-21-01Phase 4Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ferric carboxymaltose in gastric cancer (GC), sponsored by Helsinki University Hospital. Primary endpoint: Number of patients receiving transfusions. Planned start Dec 2024; status: authorised.
02
Drugs
ferric carboxymaltose
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on 2024-519738-21-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519738-21-01.